Cube Biotech GmbH announced on July 9th the appointment of Dr. Joachim Kreuzburg, former CEO and Chairman of the Executive Board of Sartorius AG, to its Board of Directors, effective July 3rd, 2025.
Dr. Kreuzburg brings over two decades of executive leadership in the life sciences industry. During his tenure as CEO of Sartorius (2003–2025), the company expanded from a regional player into a global leader in bioprocessing, growing revenue from approximately EUR 0.5 billion to approximately EUR 3.5 billion and increasing the market capitalization of the group by a factor of approximately 150.
“We are honoured to welcome Joachim to the Cube Biotech Board,” said Didier Dargent, Executive Chairman of Cube Biotech. “His strategic insights and deep sector expertise will be invaluable as we scale our global operations and advance our automation-driven capabilities in membrane protein technologies, purification and drug discovery.”
Dr. Kreuzburg added: “Cube Biotech is building a powerful platform with world-class science, strong momentum, and an entrepreneurial team. I am excited to join the Board and support its journey to become a global leader in protein research.”
Dr. Kreuzburg joined Sartorius in 1999 and served as CEO from 2003 to 2025. He chaired the board of Sartorius Stedim Biotech and currently holds board roles at Carl Zeiss AG, Otto Bock SE & Co. KGaA, and Max Planck Gesellschaft (Germany’s leading research organization).
Cube Biotech specializes in the purification, stabilization, and functional screening of membrane proteins — tackling some of the most complex drug targets in biomedical research. As enablers of drug discovery, they support scientists in unlocking the full therapeutic potential of membrane proteins.
Following their merger with IBA Life Sciences and with the strategic support of ARCHIMED, they are accelerating innovation, expanding their global reach, and streamlining services across the entire protein research value chain. Their latest advancement: a proprietary automation technology that enables scalable membrane protein production, providing researchers with the tools to drive structural biology, screening campaigns, and therapeutic development with exceptional efficiency and reproducibility.
(Source: Biotech Newswire)
